Orteronel
As of the edition of 20 October 2026, Orteronel is a small molecule: stopped in 2017; acts on CYP17A1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2017
- Kind
- Small molecule
- Registered trials
- 18, 6 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Skin and connective tissue; Hormones; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Orteronel.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CYP17A1 | Steroid 17-alpha-hydroxylase/17,20 lyase | P05093 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 12 | 6 | 0 | 6 |
| Phase 3 | 5 | 5 | 0 | 0 |
| All trials | 18 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Takeda | Lead sponsor of trials | 2008 to now |
| SCRI Development Innovations | Lead sponsor of trials | 2014 to now |